DOCSLIB.ORG

Serotonin Receptors – from Molecular Biology to Clinical Applications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Serotonin Receptors – from Molecular Biology to Clinical Applications Physiol. Res. 60: 15-25, 2011 https://doi.org/10.33549/physiolres.931903 REVIEW Serotonin Receptors – From Molecular Biology to Clinical Applications M. PYTLIAK1, V. VARGOVÁ2, V. MECHÍROVÁ1, M. FELŠÖCI1 1First Internal Clinic, Louis Pasteur University Hospital and Faculty of Medicine, Šafárik University, Košice, Slovak Republic, 2Third Internal Clinic, Louis Pasteur University Hospital and Faculty of Medicine, Šafárik University, Košice, Slovak Republic Received October 5, 2009 Accepted May 26, 2010 On-line October 15, 2010 Summary neurotransmitters at synapses of nerve cells. It has a similar Serotonin (5-hydroxytryptamine) is an ubiquitary monoamine chemical structure with tryptamine, dimethyltryptamine, acting as one of the neurotransmitters at synapses of nerve cells. diethytryptamine, melatonin and bufothein belonging to Serotonin acts through several receptor types and subtypes. The the group of indolalkylamins (Doggrell 2003). profusion of 5-HT receptors should eventually allow a better In addition to the nerve endings, serotonin was understanding of the different and complex processes in which found in the bodies of neurons, enterochromafinne serotonin is involved. Its role is expected in the etiology of stomach cells and platelets. Biosynthesis of serotonin several diseases, including depression, schizophrenia, anxiety and begins with hydroxylation of an essential amino acid panic disorders, migraine, hypertension, pulmonary hypertension, L-tryptophan. L-tryptophan is transported through the eating disorders, vomiting and irritable bowel syndromes. In the blood-brain barrier into the brain using the neutral amino past 20 years, seven distinct families of 5-HT receptors have acids transmitter, on which competes with other amino been identified and various subpopulations have been described acids – phenylalanine, leucine and methionine. for several of them. Increasing number of 5-HT receptors has Tryptophanhydroxylase is the first step and speed made it difficult to unravel the role of 5-HT receptor limiting factor of 5-HT synthesis. This enzyme was found subpopulations due to the lack of suitable selective agents. The in the brain only in the serotoninergic neurons. It enables present review describes the different populations and conversion of tryptophan into 5-hydroxytryptophan, nomenclature of recently discovered 5-HT receptors and their followed by the decarbolization mediated by aromatic pharmacological relevance. L-amino acid decarboxylase onto 5-hydroxytryptamine Key words (serotonin) – Figure 1 (Berger 2009). Serotonin • Serotonin receptors • Antidepressants • Behavior Serotonin was discovered in the late 1940s and within a next decade, there were indications for its Corresponding author existence in the central nervous system of animals and its Marek Pytliak, 1st Internal Clinic , Medical Faculty, P. J. Safarik neurotransmitter function. By the late 1950s, evidence for University, Trieda SNP 1, 040 11 Kosice, Slovak Republic. E-mail: 5-HT receptor heterogeneity was found in the periphery [email protected] and in 1979, two distinct populations of 5-HT binding sites were identified in rat brain: 5-HT1 and 5-HT2 sites Introduction (Peroutka 1984). In the recent 20 years, seven distinct families of 5-HT receptors have been identified (Table 1) Serotonin – 5-hydroxytryptamine (5-HT) is an and various subpopulations have been described for ubiquitary monoamine acting as one of the several of these (e.g. Nichols and Nichols 2008). PHYSIOLOGICAL RESEARCH • ISSN 0862-8408 (print) • ISSN 1802-9973 (online) © 2011 Institute of Physiology v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic Fax +420 241 062 164, e-mail: [email protected], www.biomed.cas.cz/physiolres 16 Pytliak et al. Vol. 60 Fig. 1. Synthesis of serotonin from tryptophan (the hydroxylation of tryptophan trough tryptophanhydroxylase is a speed limiting step in the serotonin production). Source: own figure Table 1. Families of 5-HT receptors. Family Potential Type Mechanism of action 5-HT1 Inhibitory Gi/G0-protein coupled Decreasing intracellular concentration of cAMP Increasing intracellular concentration of IP3 and 5-HT Excitatory G -protein coupled 2 q11 DAG + + 5-HT3 Excitatory Ligand-gated Na /K channel Depolarization of cell plasma membrane 5-HT4 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP 5-HT5 Inhibitory Gi/G0-protein coupled Decreasing intracellular concentration of cAMP 5-HT6 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP 5-HT7 Excitatory Gs-protein coupled Increasing intracellular concentration of cAMP IP3: inositol trisphosphate; DAG: diacylglycerol; cAMP: cyclic adenosine monophosphate. Sources: Hannon and Hoyer 2002, Berger et al. 2009 At least 20 subpopulations of 5-HT receptors the inhibition of "discharge" of neurons, regulation of the have been cloned, yet (Table 2). production of ACTH (but not prolactin), and regulation of behavior and eating (Wang et al. 2009). They play 5-HT1 receptors probably an important role in the emergence of anxiety. This group consists of five receptor subtypes This observation was confirmed by studies with knockout (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F), which are gene for this subtype of 5-HT1 receptor in mice. The structurally identical in humans to 40-63 %. There is no animals showed increased fear in many experimental 5-HT1C receptor, as it was reclassified as the 5-HT2C conditions (Klemenhagen et al. 2006). Moreover, 5-HT1A receptor. They are mostly (but not exclusively) associated antagonists (buspiron, gepiron) are used or developed for with Gi/G0 proteins and inhibit production of cAMP. the treatment of anxiety and depression. Antagonists of Fully functional 5-HT1A, 5-HT1B and 5-HT1D receptors 5-HT1A receptor and β-blocker pindolol improve the have been found in many tissues of various species effectiveness of selective serotonin reuptake inhibitors – (Hoyer and Martin 1997). SSRIs in treatment of depression (Artigas et al. 2006). The 5-HT1A receptor is the most extensively The antianxiety actions of 5-HT1A (partial) agonists may distributed of all the 5-HT receptors. In the central provide primarily presynaptic somatodendritic 5-HT1A nervous system, 5-HT1A receptors are present in high receptors (leading to reduced release of 5-HT in terminal density in the cerebral cortex, hippocampus, septum, areas), whereas the antidepressant action of 5-HT1A amygdala, and raphe nucelus, but they were proven in agents may primarily provide postsynaptic 5-HT1A small amounts in the basal ganglia and thalamus as well receptors (De Vry 1995). Certain 5-HT1A agents display (el Mestikawy et al. 1993). However, they can be found antiaggressive behavior, and measurement of the density also in myentericus plexus and whole gastrointestinal of 5-HT1A receptors in frontal cortex of suicide victims tract. In the brain, 5-HT1A receptors act as autoreceptors reveals that nonviolent suicide victims had a significantly as well as postsynaptic receptors. They are involved in higher Bmax, compared with controls and violent 2011 Serotonin Receptors 17 Table 2. Subpopulations of 5-HT receptors families. Receptor Effects and functions Agonists Antagonists 5-HT1A CNS: Aggression, Anxiety, Addiction, Appetite, buspiron, spiperone, alprenolol, Emesis, Impulsivity, Memory, Mood, Nausea, dihydroergotamine, asenapine, cyanopindolol, Nociception, Respiration, Sleep, Sociability, eltoprazine, ergotamine, iodocyanopindolol, Thermoregulation, Sexual behavior flesinoxan, flibanserin, lecozotan, methiothepin, Cardiovascular system: Blood pressure, Heart gepirone, ipsapirone, oxprenolol, pindolol, rate, Cardiovascular function, Vasoconstriction, methysergide, quetiapine, propanolol Penile erection tandospirone, urapidil, Other: Pupil dilation yohimbine, ziprasidone 5-HT1B CNS: Aggression, Anxiety, Learning, Addiction, dihydroergotamine, yohimbine, alprenolol, Locomotion, Memory, Mood, Sexual behavior eletriptan, eltoprazine, asenapine, cyanopindolol , Vessels: Pulmonary vasoconstriction, Penile ergotamine, methysergide, iodocyanopindolol, erection sumatriptan, zolmitriptan isamoltane, metergoline, methiothepin, oxprenolol, pindolol, propanolol 5-HT1D CNS: Locomotion, Anxiety sumatriptan, almotriptan, ketanserin, metergoline, Vessels: Cerebral vasoconstriction dihydroergotamine, methiothepin, rRauwolscine, eletriptan, ergotamine, ritanserin frovatriptan, methysergide, naratriptan, rizatriptan, yohimbine, zolmitriptan 5-HT1E CNS: Memory eletriptan, methysergide, methiothepin tryptamine 5-HT1F Blood Vessels: Vasoconstriction eletriptan, naratriptan, methiothepin CNS: Locomotion? Anxiety? sumatriptan 5-HT2A CNS: Anxiety, Appetite, Addiction, Cognition, bufotenin, ergonovine, aripiprazole, clozapine, Imagination, Learning, Memory, Mood, lisuride, LSD (in CNS), cyproheptadine, eplivanserin, Perception, Sexual behaviour, Sleep, mescaline, myristicin, etoperidone, iloperidone, Thermoregulation psilocin, psilocybin, ketanserin, methysergide, Smooth muscles: Contraction yohimbine mirtazapine, nefazodone, Vessels: Vasoconstriction, Vasodilation olanzapine, quetiapine, Platelets: Aggregation risperidone, ritanserin, trazodone, ziprasidone 5-HT2B CNS: Anxiety, Appetite, Sleep α-metyl-5-HT, agomelatine, asenapine, Gastrointestinal tract: GI motility fenfluramine, LSD ketanserin, LSD (PNS), Vessels: Vasoconstriction (in CNS), norfenfluramine methysergide, ritanserin, Cardiovascular system: Cardiovascular function tegaserod, yohimbine 5-HT2C CNS: Anxiety, Appetite,
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • By ANDREA PETERSEN Getty Images for Those Who Have Trouble
    By ANDREA PETERSEN Getty Images For those who have trouble sleeping, there may soon be new ways to summon the sandman. Several pharmaceutical companies are working on new approaches to treat insomnia. The compounds are meant to work differently than current leading sleep aids such as Ambien and Lunesta, which, while generally safe, can have troubling side effects because they act on many areas of the brain. By contrast, many of the drugs being developed target particular systems responsible for sleep and wakefulness. The hope is that they will have fewer side effects and less potential for addiction and cognition problems the next day. New drugs are in the works to treat insomnia, which affects 10% to 30% of Americans (and more women than men). Andrea Peterson explains. About 30% of American adults have insomnia symptoms each year, scientific studies estimate. Some 10% of the population has chronic insomnia, which is generally defined as having difficulty sleeping at least three times a week for a month or more. Chronic insomnia sufferers also feel tired, cranky or foggy-headed during the day. Insomnia comes in various forms. Some people have a tough time falling asleep and others wake in the middle of the night and have trouble getting back to sleep. Some people rise for the day too early. Insomnia can increase the risk for other conditions, including heart disease, diabetes and depression. Merck & Co. is investigating a compound that inhibits the action of orexin receptors, which in turn interferes with the activity of orexin, a chemical in the brain that produces alertness.
    [Show full text]
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders
    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
    [Show full text]
  • Prokinetics and Ghrelin for the Management of Cancer Cachexia Syndrome
    85 Review Article Prokinetics and ghrelin for the management of cancer cachexia syndrome Jimi S. Malik, Sriram Yennurajalingam Department of Palliative Care, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: S Yennurajalingam; (III) Provision of study materials or patients: S Yennurajalingam; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Sriram Yennurajalingam, MD. Department of Palliative Care, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1414, Houston, TX 77030, USA. Email: [email protected]. Abstract: Cancer cachexia (CC) is one of the most distressing syndromes for both patients and their families. CC can have an impact on patient reported quality of life and overall survival. It is often associated with symptoms such as fatigue, depressed mood, early satiety, and anorexia. Prokinetic agents have been found to improve chronic nausea and early satiety associated with CC. Among the prokinetic agents, metoclopramide is one of the best studied medications. The role of the other prokinetic agents, such as domperidone, erythromycin, haloperidol, levosulpiride, tegaserod, cisapride, mosapride, renzapride, and prucalopride is unclear for use in cachectic cancer patients due to their side effect profile and limited efficacy studies in cancer patients. There has been an increased interest in the use of ghrelin-receptor agonists for the treatment of CC. Anamorelin HCl is a highly selective, novel ghrelin receptor agonist.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • 204569Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204569Orig1s000 MEDICAL REVIEW(S) Cross Discipline Team Leader Review 3. CMC/Device Dr. Khairuzzaman found the drug product portion of the NDA to be acceptable, and without need for phase 4 commitments. Dr. Sapru’s review stated that with the exception of a pending issue concerning the control of potential genotoxic impurity (b) (4) the NDA was approvable in terms of drug substance. Dr. Suarez found that the NDA was acceptable from a biopharmaceutics perspective. The Office of Compliance issuance of an acceptable recommendation for drug substance manufacturing and testing facilities was pending at the time of this review. 4. Nonclinical Pharmacology/Toxicology Dr. Richard Siarey completed the primary nonclinical review, and Dr. Lois Freed completed a supervisory memo. Dr. Siarey’s overall conclusion was that from a nonclinical perspective, approval of the suvorexant NDA was recommended. However, he found evidence that catapelxy was observed in dogs exposed to MK-4305 (suvorexant) near Tmax, although he concluded that additional information could have been gained by studying the drug in an experimental model that has been used for diagnosing cataplexy in dogs. Dr. Siarey suggested that since cataplexy occurred in dogs near Tmax, a time at which if used for insomnia patients would ordinarily be in bed, safety concern for humans was reduced. Dr. Siarey also found that the neurobehavioral assessment in the pre- and post-natal developmental study was not complete, as the passive avoidance tests was performed too early in development, while learning/acquisition tests and retention/memory tests were not conducted.
    [Show full text]
  • The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease
    brain sciences Perspective The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease Jung Goo Lee 1,2 , Young Sup Woo 3, Sung Woo Park 2,4, Dae-Hyun Seog 5, Mi Kyoung Seo 6 and Won-Myong Bahk 3,* 1 Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan 47392, Korea; [email protected] 2 Paik Institute for Clinical Research, Department of Health Science and Technology, Graduate School, Inje University, Busan 47392, Korea; [email protected] 3 Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; [email protected] 4 Department of Convergence Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea 5 Department of Biochemistry, College of Medicine, Inje University, Busan 47392, Korea; [email protected] 6 Paik Institute for Clinical Research, Inje University, Busan 47392, Korea; [email protected] * Correspondence: [email protected] Received: 16 September 2019; Accepted: 19 October 2019; Published: 21 October 2019 Abstract: Melatonin is a hormone that is secreted by the pineal gland. To date, melatonin is known to regulate the sleep cycle by controlling the circadian rhythm. However, recent advances in neuroscience and molecular biology have led to the discovery of new actions and effects of melatonin. In recent studies, melatonin was shown to have antioxidant activity and, possibly, to affect the development of Alzheimer’s disease (AD). In addition, melatonin has neuroprotective effects and affects neuroplasticity, thus indicating potential antidepressant properties. In the present review, the new functions of melatonin are summarized and a therapeutic target for the development of new drugs based on the mechanism of action of melatonin is proposed.
    [Show full text]
  • APPENDIX a Scoping Letter, NOP, and NOP Comments
    APPENDIX A Scoping Letter, NOP, and NOP Comments THE CITY OF SAN DIEGO PLANNING DEPARTMENT Date of Notice: November 24, 2014 PUBLIC NOTICE OF THE PREPARATION OF A PROGRAM ENVIRONMENTAL IMPACT REPORT AND A SCOPING MEETING INTERNAL ORDER No. 21003411 PUBLIC NOTICE: The City of San Diego as the Lead Agency has determined that the project described below will require the preparation of a Program Environmental Impact Report (PEIR) in compliance with the California Environmental Quality Act (CEQA). This Notice of Preparation of a PEIR and Scoping Meeting was publicly noticed and distributed on November 24, 2014. This notice was published in the SAN DIEGO DAILY TRANSCRIPT and placed on the City of San Diego website at: http://www.sandiego.gov/city-clerk/officialdocs/notices/index.shtml SCOPING MEETING: Two public scoping meetings will be held by the City of San Diego's Planning Department one on Tuesday, December 9, 2014 from 5:30 p.m. to 7:30 PM at the South Bay Recreation Center located at 1885 Coronado Avenue, San Diego CA 92154, and one on Thursday, December 11, 2014 from 6:00 PM to 8:00 PM at the Public Utilities Department Metropolitan Operations Complex located at 9192 Topaz Way, San Diego CA 92123. Please note that depending on the number of attendees, the meeting could end earlier than the end times noted above. Verbal and written comments regarding the scope and alternatives of the proposed EIR will be accepted at the meeting. Please send in written/mail-in comments may also be sent to the following address: Myra Herrmann, Environmental Planner, City of San Diego Development Services Center, 1222 First Avenue, MS 501, San Diego, CA 92101 or e-mail your comments to [email protected] with the Project Name and Number in the subject line Number in the subject line within 30 days of the receipt of this notice/date of the Public Notice above.
    [Show full text]
  • The Role of the Serotonergic System and the Effects of Antidepressants During Brain Development Examined Using in Vivo Pet Imaging and in Vitro Receptor Binding
    From THE DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden THE ROLE OF THE SEROTONERGIC SYSTEM AND THE EFFECTS OF ANTIDEPRESSANTS DURING BRAIN DEVELOPMENT EXAMINED USING IN VIVO PET IMAGING AND IN VITRO RECEPTOR BINDING Stal Saurav Shrestha Stockholm 2014 Cover Illustration: Voxel-wise analysis of the whole monkey brain using the PET radioligand, [11C]DASB showing persistent serotonin transporter upregulation even after more than 1.5 years of fluoxetine discontinuation. All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice-AB © Stal Saurav Shrestha, 2014 ISBN 978-91-7549-522-4 Serotonergic System and Antidepressants During Brain Development To my family Amaze yourself ! Stal Saurav Shrestha, 2014 The Department of Clinical Neuroscience The role of the serotonergic system and the effects of antidepressants during brain development examined using in vivo PET imaging and in vitro receptor binding AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM föreläsningssalen L8:00, Karolinska Universitetssjukhuset, Solna THESIS FOR DOCTORAL DEGREE (PhD) Stal Saurav Shrestha Date: March 31, 2014 (Monday); Time: 10 AM Venue: Center for Molecular Medicine Lecture Hall Floor 1, Karolinska Hospital, Solna Principal Supervisor: Opponent: Robert B. Innis, MD, PhD Klaus-Peter Lesch, MD, PhD National Institutes of Health University of Würzburg Department of NIMH Department
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
    Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway Hongjie Zhu1., Mikhail B. Bogdanov2., Stephen H. Boyle1, Wayne Matson3, Swati Sharma3, Samantha Matson3,4, Erik Churchill1, Oliver Fiehn5, John A. Rush6, Ranga R. Krishnan1,6, Eve Pickering7, Marielle Delnomdedieu8, Rima Kaddurah-Daouk1*, Pharmacometabolomics Research Network 1 Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, United States of America, 2 Department of Neurology and Neuroscience Weill Cornell Medical College, New York, New York, United States of America, 3 Department of Systems Biochemistry, Bedford VA Medical Center, Bedford, Massachusetts, United States of America, 4 Massachusetts General Hospital, Boston, Massachusetts, United States of America, 5 Genome Center, University of California Davis, Davis, California, United States of America, 6 Duke-NUS Graduate Medical School, Singapore, Singapore, 7 Pfizer Global R&D, Clinical Research Statistics, Groton, Connecticut, United States of America, 8 Pfizer Global R&D, Neuroscience Clinical Research, Groton, Connecticut, United States of America Abstract Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17).
    [Show full text]